PMLiVE5d
AstraZeneca/Merck’s Koselugo shows promise in adults with neurofibromatosis type 1
AstraZeneca (AZ) and Merck – known as MSD outside the US and Canada – have shared positive results from a late-stage study of ...
PMLiVE4d
Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type
Merck KGaA and Abbisko Therapeutics have announced positive results from a late-stage study of pimicotinib in patients with ...
PMLiVE4d
Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn
Novartis and Schrödinger have entered into a research collaboration and licence agreement worth over $2.4bn to advance ...
PMLiVE13d
GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m
GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...
PMLiVE5d
J&J’s nipocalimab granted FDA breakthrough designation for Sjögren’s disease
Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to ...
PMLiVE7d
Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study
Novavax has announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on a late-stage study of ...
PMLiVE4d
Don’t miss out! Get a Sneak Peek at Next-Gen Life Science Education and Training Tools
From interactive case studies to AI-driven avatars, our free webinar dives into the tools defining tomorrow’s life sciences ...
PMLiVE11d
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
PMLiVE8d
AstraZeneca/Amgen’s Tezspire shows promise in phase 3 CRSwNP trial
AstraZeneca (AZ) and Amgen have shared positive results from a late-stage study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The phase 3 WAYPOINT trial ...
PMLiVE11d
NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder
The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to treat patients with the rare blood disorder systemic mastocytosis (SM). The ...
PMLiVE11d
UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance
A UK study has demonstrated that interventions to reduce respiratory syncytial virus (RSV) infections could help to reduce antibiotic prescribing and therefore antimicrobial resistance (AMR), which is ...
PMLiVE8d
FDA approves Autolus Therapeutics’ Aucatzyl to treat acute lymphoblastic leukaemia
The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat acute lymphoblastic leukaemia (ALL). The CD19-directed CAR-T cell therapy has ...